Besides the well-known palliative effects in cancer patients, cannabinoids have been shown to inhibit in vitro growth of tumor cells. Likewise, the major endocannabinoids (eCBs), anandamide (AEA) and 2-arachidonoylglycerol (2-AG), induce tumor cell death. Endometrial cancer cell lines express all the constituents of the endocannabinoid system. The data of this study indicate that cannabinoids modulate endometrial cancer cell death. Selective targeting of TPRV1 by AEA, CBD, or other stable analogues may be an attractive research area for the treatment of estrogen-dependent endometrial carcinoma. Our data further support the evaluation of CBD and CBD-rich extracts for the potential treatment of endometrial cancer, particularly, that has become non-responsive to common therapies.
Possibility of efficacy for cannabis in treatment of Cancer (Endometrial/Uterine) according to the results found in this study.
Anandamide (AEA) and 2-arachidonoylglycerol (2-AG)
Transient receptor potential vanilloid 1 (TRPV1)